Breast-conserving surgery and sentinel lymph node biopsy for breast cancer and their correlation with the expression of polyligand proteoglycan-1

Table 5 Relationship between polyligand proteoglycan-1 expression and clinicopathological characteristics of breast cancer, n (%)

Clinicopathological features	Cases	Positive expression rate of SDC-1	χ2	P value
Age (yr)			0.225	0.635
< 50	30	8 (26.67)
≥ 50	50	11 (22.00)
Course of the disease			0.133	0.716
< 12 mo	35	9 (25.71)
≥ 12 mo	45	2 (5.71)
AJCC stage			5.824	0.016
I	45	17 (37.78)
II	35	5 (14.29)
Site			0.008	0.931
Outer quadrant	47	11 (23.40)
Non outer quadrant	33	8 (24.24)
Tissue type			0.097	0.755
Invasive ductal carcinoma	57	13 (22.81)
Others	23	6 (26.09)
Treatment plan			0.084	0.771
Breast conserving surgery plus sentinel lymph node biopsy	44	11 (25.00)
Total mastectomy	36	8 (22.22)

SDC-1: Polyligand proteoglycan-1 (syndecan-1); AJCC: American Joint Committee on Cancer.